Impact of Silymarin Dosages to Decrease Drug-induced Elevated Liver Enzymes Compared to Placebo
Status:
Active, not recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
In this clinical study silymarin will be administered in different dosages and compared to
placebo in order to address if the liver protecting features of silymarin, measured by
changes of liver enzyme concentration, can be improved in patients with drug-induced elevated
liver enzymes or drug-induced hepatocellular liver injury with higher systemic
bioavailabilities due to administration of higher oral dosages or administration of higher
administration frequency over a 35-day treatment period.